昭衍新药(06127)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06127 昭衍新药

交易中 04-30 09:37:27

21.720

-1.540

-6.62%

最高24.020	最低21.660	成交量153.08万
今开23.960	昨收23.260	日振幅10.15%
总市值162.68亿	流通市值25.85亿	总股本7.49亿
成交额3,439万	换手率1.29%	流通股本1.19亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06127","market":"HK","secType":"STK","nameCN":"昭衍新药","latestPrice":21.72,"timestamp":1777513047704,"preClose":23.26,"halted":0,"volume":1530800,"delay":0,"changeRate":-0.06620808254514199,"floatShares":118995206,"shares":749000000,"eps":0.4579833249749247,"marketStatus":"交易中","change":-1.54,"latestTime":"04-30 09:37:27","open":23.96,"high":24.02,"low":21.66,"amount":34387892,"amplitude":0.101462,"askPrice":21.72,"askSize":80200,"bidPrice":21.68,"bidSize":13200,"shortable":3,"etf":0,"ttmEps":0.4579833249749247,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1777521600000},"marketStatusCode":2,"adr":0,"listingDate":1614268800000,"exchange":"SEHK","adjPreClose":23.26,"dividendRate":0.001496,"openAndCloseTimeList":[[1777512600000,1777521600000],[1777525200000,1777536000000]],"volumeRatio":15.106518,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"603127","market":"SH","secType":"STK","nameCN":"昭衍新药","latestPrice":37.16,"timestamp":1777513045000,"preClose":38.64,"halted":0,"volume":8774300,"delay":0,"premium":"-48.95"}},"requestUrl":"/m/hq/s/06127","defaultTab":"news","newsList":[{"id":"1128993137","title":"昭衍新药（06127）三十周年收入降至16.58亿元 净利润同比大幅增长逾三倍","url":"https://stock-news.laohu8.com/highlight/detail?id=1128993137","media":"公告速递","labels":["dataReport","SGX"],"top":1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128993137?lang=zh_cn&edition=full","pubTime":"2026-04-29 18:44","pubTimestamp":1777459489,"startTime":"0","endTime":"0","summary":"昭衍新药在其成立三十周年之际发布的2025年度报告显示，公司全年收入为16.58亿元人民币，较2024年的20.18亿元减少17.88%，相较2023年亦下降30.25%。受非临床研究服务需求阶段性调整等因素影响，主营业务规模相应回落。其中非临床研究服务收入约为15.77亿元，占总收入比重95.1%，临床试验及相关服务收入占比约4.4%，销售授权收入占比为0.5%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"昭衍新药（06127）三十周年收入降至16.58亿元 净利润同比大幅增长逾三倍","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155072266","title":"昭衍新药2026年第一季度营收3.16亿元，经调整净利润2.17亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1155072266","media":"公告速递","labels":["SGX"],"top":1,"itemType":null,"share":"https://www.laohu8.com/m/news/1155072266?lang=zh_cn&edition=full","pubTime":"2026-04-29 18:18","pubTimestamp":1777457914,"startTime":"0","endTime":"0","summary":"昭衍新药公布2026年第一季度业绩，营业收入为3.16亿元，同比增长10.02%。经调整净利润为2.17亿元，同比大幅增长747.11%。整体毛利率约为20.50%，经营利润率约为80.99%。经营活动产生的现金流约1.28亿元，同比提升95.88%。本季度实验室服务及其他业务贡献净利润为-2846.11万元，同比下降15.13%，主要原因在于行业竞争激烈的滞后影响，导致毛利率处于较低水平。同时，生物资产公允价值变动带来约2.46亿元净收益，是拉动整体净利润增长的关键因素。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"昭衍新药2026年第一季度营收3.16亿元，经调整净利润2.17亿元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631018591","title":"昭衍新药(06127)一季度归母净利润2.38亿元 同比增加479.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631018591","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631018591?lang=zh_cn&edition=full","pubTime":"2026-04-29 18:17","pubTimestamp":1777457867,"startTime":"0","endTime":"0","summary":"智通财经APP讯，昭衍新药(06127)发布2026年第一季度报告，营业收入3.16亿元(人民币，下同)，同比增加10.02%;归母净利润2.38亿元，同比增加479.67%;基本每股收益0.32元。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1436324.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["06127","603127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630056375","title":"4月28日昭衍新药涨7.31%，易方达医疗保健行业混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2630056375","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630056375?lang=zh_cn&edition=full","pubTime":"2026-04-28 16:23","pubTimestamp":1777364615,"startTime":"0","endTime":"0","summary":"证券之星消息，4月28日昭衍新药涨7.31%，收盘报39.95元，换手率9.65%，成交量60.83万手，成交额23.86亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共44家，其中持有数量最多的公募基金为易方达基金的易方达医疗保健行业混合A。易方达医疗保健行业混合A目前规模为32.51亿元，最新净值3.99，较上一交易日上涨0.66%，近一年上涨16.63%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042800048830.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603127","BK1576","06127","BK1141","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630132145","title":"别只盯着AI！CXO龙头绩后狂飙，医药赛道要接棒？","url":"https://stock-news.laohu8.com/highlight/detail?id=2630132145","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630132145?lang=zh_cn&edition=full","pubTime":"2026-04-28 12:12","pubTimestamp":1777349565,"startTime":"0","endTime":"0","summary":"新一轮行情蓄势待发？","market":"sg","thumbnail":"https://img3.gelonghui.com/24523-2e652654-d4de-433f-93f9-afc3a2669c93.jpg?guru_height=718&guru_width=1280&guru_size=85166","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/24523-2e652654-d4de-433f-93f9-afc3a2669c93.jpg?guru_height=718&guru_width=1280&guru_size=85166"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/4574522","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["159938","09939","02359","ARTY","BK1576","CHAT","LU0708995583.HKD","LU0348766576.USD","BK1161","AGIX","BK1574","AIPO","BK0132","BK1583","BK1515","002821","LU1328615791.USD","LU2242644610.SGD","603127","LU2045819591.USD","LU0320764599.SGD","LU2125910500.SGD","BK0216","LU0052750758.USD","LU0348767384.USD","LU1046422090.SGD","BK0239","BK1141","BK1191","06127","06821","CXO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629770147","title":"徐慕浩2026年一季度表现，泰信蓝筹精选混合基金季度涨幅4.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629770147","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629770147?lang=zh_cn&edition=full","pubTime":"2026-04-21 12:28","pubTimestamp":1776745731,"startTime":"0","endTime":"0","summary":"证券之星消息，截止2026年一季度末，基金经理徐慕浩旗下共管理2只基金，本季度表现最佳的为泰信蓝筹精选混合，季度净值涨4.09%。徐慕浩在担任泰信竞争优选混合基金经理的任职期间累计任职回报188.15%，平均年化收益率为17.16%。持有期间的估算收益率为97.47%，持有期间东方盛虹在2020年到2021年的年报归属净利润增幅达496.75%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042100025805.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06127","BK1576","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628375688","title":"每周股票复盘：昭衍新药（603127）将发布一季度业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2628375688","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628375688?lang=zh_cn&edition=full","pubTime":"2026-04-19 01:10","pubTimestamp":1776532215,"startTime":"0","endTime":"0","summary":"截至2026年4月17日收盘，昭衍新药报收于36.93元，较上周的38.28元下跌3.53%。本周，昭衍新药4月15日盘中最高价报39.97元。4月13日盘中最低价报35.51元。昭衍新药当前最新总市值276.73亿元，在医疗服务板块市值排名7/51，在两市A股市值排名783/5198。公司公告汇总H股公告：董事会召开日期北京昭衍新药研究中心股份有限公司董事会宣布，将于2026年4月29日举行董事会会议，以考虑及通过本集团截至2026年3月31日止三个月之第一季度业绩及其发布。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041900000320.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603127","BK1576","BK1141","BK0216","06127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628202527","title":"昭衍新药（603127）披露董事会将审议2026年第一季度业绩，4月17日股价下跌4.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2628202527","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628202527?lang=zh_cn&edition=full","pubTime":"2026-04-17 22:02","pubTimestamp":1776434542,"startTime":"0","endTime":"0","summary":"截至2026年4月17日收盘，昭衍新药报收于36.93元，较前一交易日下跌4.15%，最新总市值为276.73亿元。该股当日开盘37.9元，最高38.09元，最低36.8元，成交额达11.91亿元，换手率为5.09%。近日，昭衍新药发布H股公告，宣布董事会将于2026年4月29日举行会议，以考虑及通过公司集团截至2026年3月31日止三个月之第一季度业绩及其发布。公告同时列出了董事会成员名单，包括主席兼执行董事冯宇霞女士及其他执行、独立非执行与职工董事。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041700045354.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603127","BK0216","BK1576","BK1141","06127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628221164","title":"港股异动 | CXO 概念股跌幅居前 海外投融资大环境进入波动阶段 AI制药或导致研发及临床端分化","url":"https://stock-news.laohu8.com/highlight/detail?id=2628221164","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628221164?lang=zh_cn&edition=full","pubTime":"2026-04-17 11:31","pubTimestamp":1776396664,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，CXO概念股跌幅居前，截至发稿，昭衍新药跌5.82%，报21.7港元；康龙化成跌3.65%，报21.1港元；泰格医药跌3.02%，报42.46港元。中信建投发布研报称，海外投融资大环境进入季度间波动，不同阶段、不同疾病领域的CXO服务需求进一步分化，国内投融资活动景气度持续上行，弹性更强，持续看好CXO板块成长空间。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1429805.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","CXO","03347","BK4585","03759","06127","BK1141","BK1191","BK1583","CHAT","BK1576","ARTY","01477","BK4588","AGIX","AIPO","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627245420","title":"港股概念追踪 | 创新药板块迎政策东风 国办发文健全药品价格形成机制（附概念股）","url":"https://stock-news.laohu8.com/highlight/detail?id=2627245420","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627245420?lang=zh_cn&edition=full","pubTime":"2026-04-15 07:16","pubTimestamp":1776208598,"startTime":"0","endTime":"0","summary":"意见从4个方面提出14条举措，包括完善重点环节药品价格政策、推动相关主体发挥药品价格发现作用、引导关键领域药品价格保持合理水平、加强药品价格治理。具体举措包括优化创新药等新上市药品首发价格机制、发挥医保支付标准对药品价格形成的引导作用、健全药品集中带量采购价格形成机制、完善药品挂网价格管理。《意见》发布后，市场普遍认为新政将为医药产业特别是创新药带来发展新契机。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428576.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0819121731.USD","LU0039217434.USD","BK1141","LU0181495838.USD","02359","LU1046422090.SGD","BK4585","LU2242644610.SGD","LU0456827905.SGD","03347","LU0856984785.SGD","BK1583","LU0051755006.USD","LU0516422366.SGD","BK1610","LU0588546209.SGD","LU0327786744.USD","LU0516423091.SGD","02269","LU0516422440.USD","SG9999002463.SGD","06978","LU0320764599.SGD","LU0979878070.USD","LU1242518857.USD","06127","IE00B0JY6N72.USD","LU0823426308.USD","LU0348735423.USD","VXUS","LU1242518931.SGD","BK1589","LU0052750758.USD","159992","LU0708995583.HKD","LU0359202008.SGD","LU0140636845.USD","LU0359201612.USD","02315","LU0043850808.USD","LU0417516902.SGD","LU0572944931.SGD","LU0326950275.SGD","BK1161","LU0307460666.USD","LU2039709279.SGD","LU2045819591.USD","BK1574","LU0516422952.EUR","LU0348825331.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627303416","title":"4月14日昭衍新药涨5.61%，广发小盘LOF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2627303416","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627303416?lang=zh_cn&edition=full","pubTime":"2026-04-14 16:15","pubTimestamp":1776154549,"startTime":"0","endTime":"0","summary":"证券之星消息，4月14日昭衍新药涨5.61%，收盘报38.38元，换手率6.36%，成交量40.09万手，成交额14.87亿元。重仓昭衍新药的前十大公募基金请见下表：该股最近90天内共有6家机构给出评级，买入评级6家；过去90天内机构目标均价为44.32。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共43家，其中持有数量最多的公募基金为广发基金的广发小盘LOF。广发小盘LOF目前规模为57.68亿元，最新净值1.9499，较上一交易日下跌0.21%，近一年上涨44.88%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041400025377.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603127","162703","BK0216","06127","BK1576","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626168384","title":"港股异动 | 昭衍新药(06127)盘中涨超4% 安评行业或迎来量价齐升 公司新签订单金额环比持续增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2626168384","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626168384?lang=zh_cn&edition=full","pubTime":"2026-04-10 10:57","pubTimestamp":1775789879,"startTime":"0","endTime":"0","summary":"长江证券发布研报称，当前安评行业或迎来量价齐升。2025年业绩方面，昭衍新药收入16.58亿元，同比下滑17.87%；归母净利润2.98亿元，同比增长302.08%；扣非净利润3.11亿元，同比增长1221.30%。业务亮点方面，2025Q4新签订单金额爆发式增长。2025Q4单季度新签订单金额达9.60亿元，同比增长118.2%，已非常接近历史单季度最高水平。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1426930.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0216","603127","BK1576","BK4585","BK4588","BK1141","06127","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129609904","title":"昭衍新药3月股份变动月报表，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1129609904","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129609904?lang=zh_cn&edition=full","pubTime":"2026-04-08 16:25","pubTimestamp":1775636753,"startTime":"0","endTime":"0","summary":"2026年4月8日，北京昭衍新药研究中心股份有限公司披露2026年3月股份变动月报表，报告期截至2026年3月31日。公告显示，公司H股与A股合并计算的已发行股本保持不变。报告期内，公司已发行H股数量为118,995,206股，与上月一致；A股已发行数量为630,353,014股，同样未发生变化。其中，A股库存股份数量为3,173,920股，与上月相同，报告期内无新增发行、回购或注销安排。公司指出，截至3月底，各类股本结构与数量仍维持稳定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624659313","title":"昭衍新药（603127）披露股票交易异常波动公告，4月3日股价上涨0.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624659313","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624659313?lang=zh_cn&edition=full","pubTime":"2026-04-03 17:24","pubTimestamp":1775208259,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，昭衍新药报收于36.6元，较前一交易日上涨0.41%，最新总市值为274.26亿元。该股当日开盘36.16元，最高37.25元，最低35.03元，成交额达15.89亿元，换手率为6.92%。公司于2026年4月1日披露《股票交易异常波动公告》。公告显示，昭衍新药股票于2026年3月27日、3月30日和3月31日连续3个交易日内收盘价格涨幅偏离值累计超过20%，构成股票交易异常波动。董事会确认无应披露未披露事项。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300034308.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1141","BK1576","BK0216","603127","06127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624543215","title":"去年下半年增持昭衍新药、建仓特宝生物 中欧基金葛兰自购旗下独管医药基金","url":"https://stock-news.laohu8.com/highlight/detail?id=2624543215","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624543215?lang=zh_cn&edition=full","pubTime":"2026-04-01 07:27","pubTimestamp":1774999620,"startTime":"0","endTime":"0","summary":"2025年下半年，葛兰旗下3只基金的内部持有情况出现明显分化。3月31日，中欧基金投资总监、明星基金经理葛兰在管的3只公募基金披露2025年报，其隐形重仓股也随之曝光。具体来看，同为医药主题的中欧医疗健康、中欧医疗创新均大幅增持了昭衍新药，同时中欧医疗创新还重新买回了奥浦迈、博腾股份、三生国健，并首次建仓特宝生物。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604013690999074.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604013690999074.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["603127","688278","BK0239","BK1576","160635","BK1141","BK0216","06127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623079833","title":"昭衍新药：股票交易异常波动","url":"https://stock-news.laohu8.com/highlight/detail?id=2623079833","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623079833?lang=zh_cn&edition=full","pubTime":"2026-03-31 17:35","pubTimestamp":1774949701,"startTime":"0","endTime":"0","summary":"南财智讯3月31日电，昭衍新药公告，公司股票于2026年3月27日、3月30日和3月31日连续3个交易日内收盘价格涨幅偏离值累计超过20%，构成股票交易异常波动。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603313690516776.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1576","BK1141","603127","06127","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623379186","title":"CXO概念股强势 凯莱英(06821)涨13.85% 机构认为CXO基本面拐点已经出现","url":"https://stock-news.laohu8.com/highlight/detail?id=2623379186","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623379186?lang=zh_cn&edition=full","pubTime":"2026-03-31 10:23","pubTimestamp":1774923794,"startTime":"0","endTime":"0","summary":"金吾财讯 | CXO概念股强势，凯莱英(06821)涨13.85%，昭衍新药(06127)涨7.34%，药明生物(02269)涨5.99%，康龙化成(03759)涨4.54%，药明康德(02359)涨4.12%，泰格医药(03347)涨2.89%，金斯瑞生物科技(01548)涨1.09%。浙商医药团队分析指出，在CXO产业持续出清，股价相对低位背景下，看好本土头部CDMO企业和受益国内需求复苏CRO企业底部投资机会。从财务、需求和供给数据分析，该机构认为CXO基本面拐点已经出现，并有望持续复苏。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/YjA5ZTU5M2U3ZjIyNGI4Mzk2MWM1NGUyNWZkZjFmMjE3MzEwNTIzMzcxNTY=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YjA5ZTU5M2U3ZjIyNGI4Mzk2MWM1NGUyNWZkZjFmMjE3MzEwNTIzMzcxNTY=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977810","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0588546209.SGD","LU1242518857.USD","LU0348825331.USD","LU0417516738.SGD","LU0051755006.USD","LU0307460666.USD","06127","IE00B0JY6N72.USD","LU0181495838.USD","BK1589","LU1046422090.SGD","LU0456827905.SGD","06821","LU0516423091.SGD","LU0516422366.SGD","HK0000306701.USD","LU0856984785.SGD","LU0359201612.USD","BK1576","LU1328615791.USD","LU2045819591.USD","LU0819121731.USD","02269","01548","LU0979878070.USD","LU0327786744.USD","LU0572944931.SGD","LU0516422440.USD","LU0320764599.SGD","LU1794554557.SGD","LU1880383366.USD","LU3063872942.SGD","HK0000306685.HKD","002821","LU0823426308.USD","03347","CXO","LU0456846285.SGD","LU0516423174.USD","03759","LU0348735423.USD","LU0052750758.USD","LU0823426480.USD","02359","LU0043850808.USD","LU1688375341.USD","LU0140636845.USD","BK1521","LU0039217434.USD","LU0326950275.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109731579","title":"港股异动 | 医药外包概念走强，昭衍新药绩后涨超13%，凯莱英涨超11%","url":"https://stock-news.laohu8.com/highlight/detail?id=1109731579","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109731579?lang=zh_cn&edition=full","pubTime":"2026-03-31 09:51","pubTimestamp":1774921897,"startTime":"0","endTime":"0","summary":"3月31日，医药外包概念走强，$昭衍新药(06127)$涨超13%，$凯莱英(06821)$涨超11%，$康龙化成(03759)$涨超6%，$药明生物(02269)$、$泰格医药(03347)$涨超5%","market":"hk","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"ee4d118e55b1b421073820cd0cff0613","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06821","BK0132","BK4585","BK0216","BK4588","09939","BK1515","BK1576","BK1574","LU1328615791.USD","06127","BK1141","BK1161","BK1191","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102230524","title":"异动解读 | 昭衍新药盘中大涨5.29%，年度净利润飙升302%提振股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1102230524","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102230524?lang=zh_cn&edition=full","pubTime":"2026-03-31 09:42","pubTimestamp":1774921350,"startTime":"0","endTime":"0","summary":"昭衍新药今日盘中股价大幅上涨5.29%，引起了市场的广泛关注。消息面上，公司于近期发布了2025年年度业绩报告。报告显示，尽管营业收入同比有所下降，但归属于公司股东的净利润达到2.98亿元人民币，同比大幅增长302.1%。根据业绩公告，公司2025年扣除非经常性损益后的净利润同比增长高达1221.30%，经营活动产生的现金流量净额也实现了31.17%的同比增长。此外，公司在手订单及新签订单金额均维持在约26亿元人民币的水平，显示了其业务的稳定性。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"ee4d118e55b1b421073820cd0cff0613","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["06127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623366376","title":"港股异动 | 昭衍新药(06127)早盘涨超14% 全年纯利同比增超3倍 实验猴涨价贡献近5亿元利润","url":"https://stock-news.laohu8.com/highlight/detail?id=2623366376","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623366376?lang=zh_cn&edition=full","pubTime":"2026-03-31 09:37","pubTimestamp":1774921027,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，昭衍新药(06127)早盘涨超14%，截至发稿，涨14.54%，报22.3港元，成交额7651.06万港元。消息面上，昭衍新药发布年度业绩，2025年，公司实现营业收入16.58亿元，同比下降17.87%；归属于上市公司股东的净利润2.98亿元，同比增长302.08%。另外，公司整体在手订单金额约为26亿元，新签订单金额约为26亿元，同比均有所增长。公告显示，净利润的增长主要源于生物资产公允价值变动带来的收益。期内，生物资产公允价值变动带来净收益4.76亿元。据悉，昭衍新药的生物资产主要是用于非临床项目评价的非人灵长类实验模型，也就是所谓的“实验猴”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"ee4d118e55b1b421073820cd0cff0613","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1422706.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK4588","603127","BK1141","BK1576","06127","VXUS","BK0216"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0113},{"period":"1month","weight":0.1947},{"period":"3month","weight":-0.0017},{"period":"6month","weight":0.0849},{"period":"1year","weight":1.3974},{"period":"ytd","weight":0.1291}],"compareEarnings":[{"period":"1week","weight":-0.002},{"period":"1month","weight":0.055},{"period":"3month","weight":-0.0664},{"period":"6month","weight":0.0079},{"period":"1year","weight":0.1865},{"period":"ytd","weight":0.0188}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"北京昭衍新药研究中心股份有限公司是一家主要从事新药药理毒理学研究的中国公司。该公司通过三个分部开展业务。药物非临床研究服务分部主要提供药品非临床安全性评价服务、药效学研究服务、药代动力学研究服务。临床服务及其他分部主要提供药品上市前的临床服务以及药物警戒服务。实验模型供应分部为实验模型及其附属产品的生产和销售。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.052832},{"month":2,"riseRate":0.6,"avgChangeRate":0.086342},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.020364},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.060643},{"month":5,"riseRate":0.8,"avgChangeRate":0.111301},{"month":6,"riseRate":0.6,"avgChangeRate":0.067356},{"month":7,"riseRate":0.8,"avgChangeRate":0.10434},{"month":8,"riseRate":0,"avgChangeRate":-0.152531},{"month":9,"riseRate":0.6,"avgChangeRate":0.016217},{"month":10,"riseRate":0.2,"avgChangeRate":-0.062992},{"month":11,"riseRate":0.4,"avgChangeRate":0.019594},{"month":12,"riseRate":0.6,"avgChangeRate":0.001916}],"exchange":"SEHK","name":"昭衍新药","nameEN":"JOINN"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"昭衍新药(06127)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供昭衍新药(06127)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"昭衍新药,06127,昭衍新药股票,昭衍新药股票老虎,昭衍新药股票老虎国际,昭衍新药行情,昭衍新药股票行情,昭衍新药股价,昭衍新药股市,昭衍新药股票价格,昭衍新药股票交易,昭衍新药股票购买,昭衍新药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"昭衍新药(06127)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供昭衍新药(06127)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}